Nikolaos Marinakis | Neurogenetics | Best Researcher Award

Dr. Nikolaos Marinakis | Neurogenetics | Best Researcher Award

Dr. Nikolaos Marinakis,  Laboratory of Medical Genetics, NKUA, Greece.

Dr. Nikolaos M. Marinakis is a highly accomplished Molecular Biologist and Geneticist whose career has been devoted to the diagnosis and molecular analysis of rare genetic disorders. With over a decade of laboratory experience and a strong academic background, he has steadily advanced from early bench research in molecular biology to become a Clinical Laboratory Geneticist and genome analyst. His expertise spans whole exome and whole genome sequencing, variant interpretation, CNV and RNA sequencing analysis, and the clinical application of Next Generation Sequencing. Notably, he has contributed to over 1500 molecular diagnoses in patients with rare diseases and has gained international recognition through the ESHG observership at Radboud University Medical Center. Dr. Marinakis exemplifies scientific excellence, clinical impact, and collaborative innovation in human genetics.

Profile

Google Scholar

 

🎓 Early Academic Pursuits

Dr. Nikolaos M. Marinakis embarked on his academic journey with a strong passion for understanding human biology at a molecular level. He earned his Bachelor’s degree in Molecular Biology and Genetics from the Democritus University of Thrace (DUTH), where he was actively involved in bench research. His undergraduate thesis focused on the functional characterization of NAT1 polymorphisms in the primate Macaca mulatta, offering an early glimpse into his interest in gene function and enzyme activity. This formative research cultivated his technical proficiency in cloning, site-directed mutagenesis, protein purification, and enzymatic assays—skills that would later become instrumental in his advanced academic and clinical endeavors.

🧬 Professional Endeavors in Genetics

Dr. Marinakis has spent more than a decade immersed in both research and clinical laboratories, gaining broad and deep expertise in molecular diagnostics. His professional foundation was laid at the Laboratory of Medical Genetics at St. Sophia’s Children Hospital, affiliated with the National and Kapodistrian University of Athens (NKUA). Here, he progressed from an MSc student to a PhD candidate and eventually to a Scientific Research Associate. His doctoral research was centered on the use of Next Generation Sequencing (NGS) technologies for diagnosing rare genetic disorders, and his project involved bioinformatic evaluation and functional validation of genomic variants. As a current genome analyst, he supervises Clinical Whole Exome Sequencing, routinely interpreting variants in over 1,500 complex diagnostic cases encompassing neurodevelopmental, nephrological, cardiovascular, and ophthalmological diseases.

🔍 Research Contributions and Focus

Dr. Marinakis’s primary research lies at the intersection of clinical genomics and bioinformatics. His scientific focus is on the molecular investigation of rare monogenic disorders, variant classification, and the integration of novel genomic technologies such as long-read sequencing into diagnostic pipelines. He has also contributed to the development and clinical implementation of molecular assays for both postnatal and prenatal diagnostics. His research continues to unravel the genetic underpinnings of syndromes with previously unknown etiologies, enriching the understanding of human genomic complexity. Through RNA sequencing and CNV analysis, he bridges the gap between genotype and phenotype in a clinical context.

🏅 Accolades and Recognition

In recognition of his significant contributions to human genetics, Dr. Marinakis was awarded a competitive observership by the European Society of Human Genetics (ESHG). This prestigious award enabled him to join the Genome Diagnostics unit at the Radboud University Medical Center in the Netherlands under the mentorship of Professor Christian Gilissen. There, he expanded his expertise in whole genome sequencing, variant annotation, structural variation, and advanced bioinformatic pipelines. His growing recognition as a Clinical Laboratory Geneticist (ErCLG-certified) further underscores his professional standing in Europe’s genetics community.

🧠 Impact on Clinical Genomics

Dr. Marinakis has made a measurable impact on translational medicine by bringing genomic science to the bedside. Through his analysis and interpretation of complex NGS datasets, he has helped diagnose hundreds of patients with elusive genetic conditions, directly improving clinical outcomes and enabling personalized treatment strategies. His ability to convert raw genomic data into meaningful clinical insights has made him a key figure in the field of diagnostic genetics in Greece and beyond. His meticulous approach to variant interpretation, especially in challenging or ambiguous cases, continues to guide clinicians in the decision-making process.

🌍 Influence and Collaboration

A committed collaborator and lifelong learner, Dr. Marinakis maintains strong academic and clinical ties with global institutions. His experiences at NKUA and Radboud UMC have equipped him with a broad international outlook on genomics and rare disease research. He actively contributes to cross-border initiatives and research consortiums focused on data sharing, standardization of bioinformatics pipelines, and discovery of novel disease mechanisms. His LinkedIn presence and professional engagement reflect his dedication to connecting with the wider genetics and biomedical community.

🔮 Legacy and Future Contributions

Looking ahead, Dr. Marinakis is poised to lead initiatives that integrate AI-driven genomic interpretation and third-generation sequencing into clinical practice. He aspires to contribute to national and European genomics strategies aimed at early diagnosis, carrier screening, and reproductive planning. By mentoring younger scientists and continuing to publish translational research, he is building a legacy rooted in both scientific rigor and compassionate care. With his strong foundation and forward-thinking vision, Dr. Marinakis represents a dynamic force in the future of precision medicine and rare disease diagnostics.

Publication

  • Title: Phenotype‐driven variant filtration strategy in exome sequencing toward a high diagnostic yield and identification of 85 novel variants in 400 patients with rare Mendelian disorders
    Authors: NM Marinakis, M Svingou, D Veltra, K Kekou, C Sofocleous, FN Tilemis, …
    Year: 2021

 

  • Title: Germline CNV detection through whole-exome sequencing (WES) data analysis enhances resolution of rare genetic diseases
    Authors: FN Tilemis, NM Marinakis, D Veltra, M Svingou, K Kekou, A Mitrakos, …
    Year: 2023

 

  • Title: Case report: a novel synonymous ARPC1B gene mutation causes a syndrome of combined immunodeficiency, asthma, and allergy with significant intrafamilial clinical heterogeneity
    Authors: I Papadatou, N Marinakis, E Botsa, M Tzanoudaki, M Kanariou, I Orfanou, …
    Year: 2021

 

  • Title: The clinical and genetic spectrum of autosomal-recessive TOR1A-related disorders
    Authors: A Saffari, T Lau, H Tajsharghi, EG Karimiani, A Kariminejad, S Efthymiou, …
    Year: 2023

 

  • Title: Expanded phenotypic spectrum of neurodevelopmental and neurodegenerative disorder Bryant-Li-Bhoj syndrome with 38 additional individuals
    Authors: DE Layo-Carris, EE Lubin, AK Sangree, KJ Clark, EL Durham, …
    Year: 2024

 

  • Title: De novo variants in RNF213 are associated with a clinical spectrum ranging from Leigh syndrome to early-onset stroke
    Authors: T Brunet, B Zott, V Lieftüchter, D Lenz, A Schmidt, P Peters, R Kopajtich, …
    Year: 2024

 

  • Title: SDH-deficient renal cell carcinoma: A case report associated with a novel germline mutation
    Authors: V Milionis, D Goutas, D Vlachodimitropoulos, AC Lazaris, I Kyriazis, …
    Year: 2021

 

  • Title: Towards a standard benchmark for variant and gene prioritisation algorithms: PhEval-Phenotypic inference Evaluation framework
    Authors: Y Bridges, V de Souza, KG Cortes, M Haendel, NL Harris, DR Korn, …
    Year: 2024

 

  • Title: Bi-allelic genetic variants in the translational GTPases GTPBP1 and GTPBP2 cause a distinct identical neurodevelopmental syndrome
    Authors: V Salpietro, R Maroofian, MS Zaki, J Wangen, A Ciolfi, S Barresi, …
    Year: 2024

 

  • Title: Combined exome analysis and exome depth assessment achieve a high diagnostic yield in an epilepsy case series, revealing significant genomic heterogeneity and novel mechanisms
    Authors: D Veltra, FN Tilemis, NM Marinakis, M Svingou, A Mitrakos, K Kosma, …
    Year: 2023

 

✅ Conclusion

Dr. Nikolaos M. Marinakis stands out as a distinguished researcher in the field of medical genetics and genomics. His work bridges cutting-edge molecular research with clinical diagnostics, making a direct impact on patient care and the understanding of rare diseases. His technical expertise, international collaborations, and growing leadership in genomic diagnostics reflect both his current achievements and his potential for future contributions to precision medicine. He is a strong candidate for recognition in any academic or professional forum honoring excellence in translational genomics and biomedical research.

Jagadeesh Rao | Neuropharmacology | Best Researcher Award

Dr. Jagadeesh Rao | Neuropharmacology | Best Researcher Award

Dr. Jagadeesh Rao,  IGC Pharma LLC, United States.

Dr. Jagadeesh S. Rao is a distinguished neuroscientist and clinical researcher with over 15 years of experience in neuroscience, psychiatry, neuropharmacology, and drug development. His career is marked by significant contributions to the understanding and treatment of neurodegenerative diseases, especially Alzheimer’s disease. With a strong academic foundation in molecular biology and biochemistry, Dr. Rao has led groundbreaking work in clinical trial design, preclinical toxicology, and regulatory submissions, including IND and CMC documentation for FDA approvals. He currently serves as Principal Scientist at IGC Pharma Inc., where he leads teams in Phase I and II clinical trials, manages CROs and budgets, and has developed both OTC and investigational drug products.

Profile

Orcid

🧠 Early Academic Pursuits

Dr. Jagadeesh S. Rao began his scientific journey with a deep interest in the complexities of the human brain and molecular biology. From the early stages of his academic training, he demonstrated exceptional dedication to exploring the interplay between neurobiology, biochemistry, and psychiatric health. His pursuit of a Ph.D. laid a robust foundation in neuroscience and neuropharmacology, equipping him with a multidisciplinary understanding of the cellular and molecular mechanisms that underlie neurodegenerative and neuropsychiatric disorders. This strong academic grounding would later become the driving force behind his innovative contributions to research in pain, Alzheimer’s disease, and drug development.

🧪 Professional Endeavors in Neuroscience and Drug Development

With over 15 years of professional experience, Dr. Rao has successfully navigated and led multiple domains including toxicology, psychiatry, and molecular biology. Currently serving as a Principal Scientist at IGC Pharma Inc., he has taken a prominent role in advancing clinical drug development, particularly in designing and executing Phase I and II trials. His expertise extends to critical regulatory processes such as Investigational New Drug (IND) submissions, clinical protocol design, and Chemistry, Manufacturing, and Controls (CMC). He has actively led teams in drug formulation, batch production, validation, and compliance with FDA and ISO standards—demonstrating a blend of scientific acumen and regulatory insight.

🧬 Contributions and Research Focus in Neuropharmacology

Dr. Rao’s research centers on developing therapeutic interventions for neurodegenerative and neuropsychiatric conditions, especially Alzheimer’s disease. His contributions span the full spectrum of drug development: from preclinical toxicology and pharmacokinetics to clinical pharmacodynamics and regulatory documentation. He has designed preclinical studies adhering to GLP standards, involving mutagenesis assays, reproductive and general toxicity assessments, and immunogenicity tests. Moreover, he played a key role in the development of over-the-counter (OTC) pain relief cream products, contributing both to academic research and commercial innovation. His insights into P450 enzyme polymorphisms and their effects on drug metabolism showcase a precision medicine approach to pharmacological care.

🏅 Accolades and Recognition in Clinical Research

While much of Dr. Rao’s work has been behind the scenes of scientific advancement and regulatory excellence, his leadership in preparing CMC documents and overseeing investigational drug submissions has earned him widespread respect among peers. His oversight of departmental budgets and his management of Clinical Research Organizations (CROs) reflect not only scientific brilliance but also strategic and financial stewardship in clinical drug development. The successful initiation of Phase I and II clinical trials under his guidance stands as a testament to his expertise and diligence in the field.

🌍 Impact and Influence in Translational Medicine

Dr. Rao’s work bridges the gap between laboratory research and clinical application. His projects have advanced the translational medicine field by offering therapeutic candidates that move seamlessly from preclinical safety assessments to human trials. His influence is felt not only through the innovative drugs developed under his watch but also in shaping protocols that align with FDA’s stringent regulatory frameworks. His understanding of the molecular intricacies of neuropsychiatric diseases allows him to propose and test interventions that directly respond to the unmet needs of patients and healthcare systems alike.

🔬 Legacy in Scientific Rigor and Innovation

One of Dr. Rao’s enduring legacies lies in his rigorous approach to clinical pharmacology and his commitment to quality and safety in every phase of drug development. His ability to interpret complex PK/PD data, assess drug-drug interactions, and foresee adverse events has significantly shaped safer and more effective drug protocols. He has also contributed to the creation of technical documentation and risk assessments that serve as gold standards in the field, ensuring compliance and reproducibility for future scientists and clinicians.

🚀 Future Contributions and Vision for Neurotherapeutics

Looking ahead, Dr. Rao continues to pave the way in neurotherapeutics with a focused ambition to develop treatments for cognitive and behavioral disorders rooted in neuroinflammation and synaptic dysfunction. His vision includes refining clinical strategies using personalized medicine models and leveraging his expertise in biochemistry and molecular neuropharmacology. As the global demand for effective neurological therapies increases, Dr. Rao’s evolving research and leadership promise to yield transformative solutions that will benefit countless patients worldwide.

Publication

1. Title: Neurobiological alteration in agitation in Alzheimer’s disease and possible interventions
Author(s): Rao, Jagadeesh S.; Tangarife, Maria Alejandra; Mukunda, Ram
Year: 2024

2. Title: Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brain
Author(s): Kim, Hyung-Wook; Cheon, Yewon; Modi, Hiren R.; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2012

3. Title: Epigenetic modifications in frontal cortex from Alzheimer’s disease and bipolar disorder patients
Author(s): Rao, J. S.; Keleshian, V. L.; Klein, S.; Rapoport, S. I.
Year: 2012

4. Title: Gabapentin’s minimal action on markers of rat brain arachidonic acid metabolism agrees with its inefficacy against bipolar disorder
Author(s): Reese, Edmund A.; Cheon, Yewon; Ramadan, Epolia; Kim, Hyung-Wook; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.; Taha, Ameer Y.
Year: 2012

5. Title: Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder
Author(s): Ramadan, Epolia; Basselin, Mireille; Rao, Jagadeesh S.; Chang, Lisa; Chen, Mei; Ma, Kaizong; Rapoport, Stanley I.
Year: 2012

6. Title: Altered Expression of G-protein subunits and GRKs in Alzheimer’s Disease
Author(s): Reese, Edmund A.; Kim, Hyung-Wook; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2011

7. Title: Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain
Author(s): Cheon, Yewon; Park, Jee-Young; Modi, Hiren R.; Kim, Hyung-Wook; Lee, Ho-Joo; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.
Year: 2011

8. Title: Dietary n-6 PUFA deprivation downregulates arachidonate but upregulates docosahexaenoate metabolizing enzymes in rat brain
Author(s): Kim, Hyung-Wook; Rao, Jagadeesh S.; Rapoport, Stanley I.; Igarashi, Miki
Year: 2011

9. Title: Disturbed Choline Plasmalogen and Phospholipid Fatty Acid Concentrations in Alzheimer’s Disease Prefrontal Cortex
Author(s): Igarashi, Miki; Ma, Kaizong; Gao, Fei; Kim, Hyung-Wook; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2011

10. Title: Olanzapine Decreases Brain Arachidonic Acid (AA) Metabolism in Rats by Reducing Plasma Availability of AA
Author(s): Cheon, Yewon; Modi, Hiren R.; Park, Jee-Young; Kim, Hyung-Wook; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.
Year: 2011

✅Conclusion

Dr. Rao’s career reflects a powerful blend of scientific innovation, regulatory excellence, and clinical insight. His dedication to developing safe and effective neurological therapeutics has significantly advanced the field of translational medicine. As a leader, mentor, and researcher, his ongoing work continues to influence modern approaches to treating complex brain disorders, setting a high standard for future neuropharmacological research and therapeutic innovation.

Hao Lai | Clinical Neuroscience | Best Researcher Award

Prof. Dr. Hao Lai | Clinical Neuroscience | Best Researcher Award

Prof. Dr. Hao Lai, Zhongshan Hospital, Fudan University, China.

Dr. Hao Lai is a distinguished cardiovascular surgeon and researcher, currently serving as Chief Physician at Zhongshan Hospital, Fudan University. With over 20 years of clinical expertise, he specializes in aortic and cardiovascular surgery. His academic achievements include a Ph.D. in Surgery from Fudan University and significant contributions to the study of epigenetic mechanisms in thoracic aortic dissection. As a principal investigator of nationally funded projects and co-author of influential publications, Dr. Lai combines scientific rigor with clinical innovation. He has also played a key role in medical education and device development through industry collaboration.

Profile

Scopus

 

🎓 Early Academic Pursuits

Dr. Hao Lai began his academic journey with a strong foundation in medical sciences, culminating in a Ph.D. in Surgery from the prestigious Fudan University. His early academic pursuits were marked by a deep interest in cardiovascular physiology and surgical intervention, which later matured into a specialized focus on aortic diseases. His time as a doctoral candidate not only equipped him with rigorous scientific training but also ignited his lifelong commitment to solving complex clinical problems through research.

🏥 Professional Endeavors

Currently serving as Chief Physician at Zhongshan Hospital, Fudan University, Dr. Hao Lai has accumulated over two decades of extensive clinical experience in cardiovascular and aortic surgery. His professional trajectory reflects a seamless integration of surgical excellence with academic leadership. At Zhongshan Hospital, a leading institution in China, he has spearheaded several clinical programs aimed at enhancing patient outcomes in cases of thoracic aortic dissection and other high-risk cardiovascular conditions.

🔬 Contributions and Research Focus

Dr. Lai’s research centers around the epigenetic mechanisms underlying thoracic aortic dissection, with a particular focus on histone modification and DNA methylation. He is the Principal Investigator of a major research project funded by the National Natural Science Foundation of China, which explores the role of H3K36me3 histone modification and DNMT3B-mediated gene body methylation in the pathogenesis of aortic dissection. His scientific efforts bridge molecular pathology with clinical implications, offering new perspectives on the diagnosis and treatment of life-threatening vascular disorders.

🏆 Accolades and Recognition

A respected voice in cardiovascular medicine, Dr. Hao Lai has co-authored numerous influential articles in high-impact journals such as Cardiovascular Research and Advanced Science. His h-index of 18, as listed on Scopus, reflects his consistent scholarly output and the wide academic acknowledgment of his work. In addition, his authorship of the textbook Practical Surgery (3rd Edition), published by People’s Medical Publishing House, stands as a testament to his educational contributions to the next generation of Chinese surgeons.

🧪 Impact and Innovation

Dr. Lai’s research has made a tangible impact on the understanding and treatment of aortic diseases. His investigation into the epigenetic regulation of vascular pathology has opened new avenues for targeted therapies. Moreover, his collaboration with MicroPort Endovascular MedTech demonstrates his commitment to translating research findings into real-world applications, particularly in the development and refinement of endovascular surgical devices.

🌍 Influence and Collaboration

Beyond his direct research and surgical contributions, Dr. Lai’s influence extends into collaborative domains, both nationally and internationally. His leadership in high-level research grants, clinical trials, and industrial partnerships positions him as a central figure in the evolving landscape of cardiovascular surgery. His collaborative spirit fosters innovation and promotes cross-disciplinary dialogue, essential in today’s complex medical research environment.

🔮 Legacy and Future Contributions

As Dr. Hao Lai continues his distinguished career, his legacy is being shaped not only by his surgical accomplishments but also by his contributions to medical science. His ongoing projects are likely to further clarify the molecular landscape of aortic diseases and inspire new therapeutic strategies. Looking ahead, Dr. Lai is poised to remain at the forefront of cardiovascular innovation, committed to improving patient care through a synthesis of research, education, and clinical practice.

Publication

 

Title: Prevalence and predictors of left atrial thrombus in patients with rheumatic atrial fibrillation undergoing cardiac surgery: a cross-sectional study
Authors: J. Cui, Y. Zhang, Y. Wang, Q. Ji, C. Wang
Year: 2025


Title: A novel open-vascular single-branched stent graft in total arch repair of type A aortic dissection one-year results of a prospective multicenter randomized controlled study
Authors: J. Gu, W. Zhang, L. Kang, H. Lai, C. Wang
Year: 2025


Title: Fibroblast Activation Protein Acts as a Biomarker for Monitoring ECM Remodeling During Aortic Aneurysm via 68Ga-FAPI-04 PET Imaging
Authors: C. Hu, H. Tan, Y. Zhang, X. Chen, L. Wang
Year: 2025


Title: Mitochondrial NAD+ deficiency in vascular smooth muscle impairs collagen III turnover to trigger thoracic and abdominal aortic aneurysm
Authors: J. Zhang, Y. Tang, S. Zhang, K. Zhu, W. Zhang
Year: 2025


Title: Correcting mitochondrial loss mitigates NOTCH1-related aortopathy in mice
Authors: Y. Tang, J. Zhang, Y. Fang, Y. Xu, W. Zhang
Year: 2025


Title: Exploration of 68Ga-FAPI-04 PET/MR in Chronic Type B Aortic Dissection
Authors: C. Hu, Y. Zhang, S. Qiu, H. Shi, L. Wang
Year: 2025


Title: Effects of postoperative glucocorticoids on mitigation of organ dysfunction in patients with type A aortic dissection: A randomized controlled trial
Authors: M. Luo, J. Luo, X. Xu, G. Tu, Z. Luo
Year: 2024


Title: Therapeutic results of three-dimensional aortic valve anatomic repair for regurgitant bicuspid aortic valve
Authors: J. Li, C. Wang, Z. Zuo, W. Ding, T. Hong
Year: 2024


Title: 68Ga-FAPI-04 Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Ascending Aortic Aneurysm
Authors: C. Hu, H. Tan, Y. Zhang, H. Lai, L. Wang
Year: 2024


Title: Sex-based outcomes after thoracic endovascular aortic repair: A systematic review and meta-analysis
Authors: Y. Zhang, Y. Zhang, Y. Wang, L. Wang, Q. Ji
Year: 2025

✅ Conclusion

Dr. Hao Lai’s career represents a powerful blend of surgical precision, scientific insight, and academic leadership. His work has advanced the understanding of aortic diseases at the molecular level while improving surgical outcomes for patients. As he continues to mentor, innovate, and lead research at the intersection of epigenetics and cardiovascular pathology, Dr. Lai’s contributions are set to leave a lasting legacy in both clinical practice and medical science.